BIVI8:00 AMBioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVIDEnrollmentbioviepharma.com
BIVI8:00 AMBioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s DiseaseEnrollment • Phase 2bioviepharma.com